These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16159021)

  • 1. Creating the next generation of protein therapeutics through rational drug design.
    Szymkowski DE
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody cocktails: next-generation biopharmaceuticals with improved potency.
    Logtenberg T
    Trends Biotechnol; 2007 Sep; 25(9):390-4. PubMed ID: 17681390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of next-generation protein therapeutics.
    Caravella J; Lugovskoy A
    Curr Opin Chem Biol; 2010 Aug; 14(4):520-8. PubMed ID: 20638324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation biopharmaceuticals.
    Walsh G
    Eur J Pharm Biopharm; 2004 Sep; 58(2):185-96. PubMed ID: 15296948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic advances in rheumatology with the use of recombinant proteins.
    Rothe A; Power BE; Hudson PJ
    Nat Clin Pract Rheumatol; 2008 Nov; 4(11):605-14. PubMed ID: 18813220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we rationally design promiscuous drugs?
    Hopkins AL; Mason JS; Overington JP
    Curr Opin Struct Biol; 2006 Feb; 16(1):127-36. PubMed ID: 16442279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging classes of protein-protein interaction inhibitors and new tools for their development.
    Pagliaro L; Felding J; Audouze K; Nielsen SJ; Terry RB; Krog-Jensen C; Butcher S
    Curr Opin Chem Biol; 2004 Aug; 8(4):442-9. PubMed ID: 15288255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DARPins: a new generation of protein therapeutics.
    Stumpp MT; Binz HK; Amstutz P
    Drug Discov Today; 2008 Aug; 13(15-16):695-701. PubMed ID: 18621567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directed evolution of novel protein functions.
    Zhao H
    Biotechnol Bioeng; 2007 Oct; 98(2):313-7. PubMed ID: 17721862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of immunotoxins: current progress and future prospects.
    Wawrzynczak EJ
    Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing scaleup yield for protein production: Computationally Optimized DNA Assembly (CODA) and Translation Engineering.
    Hatfield GW; Roth DA
    Biotechnol Annu Rev; 2007; 13():27-42. PubMed ID: 17875472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational optimization of proteins as drugs: a new era of 'medicinal biology'.
    Szymkowski DE
    Drug Discov Today; 2004 May; 9(9):381-3. PubMed ID: 15081952
    [No Abstract]   [Full Text] [Related]  

  • 15. High-throughput screening for enhanced protein stability.
    Bommarius AS; Broering JM; Chaparro-Riggers JF; Polizzi KM
    Curr Opin Biotechnol; 2006 Dec; 17(6):606-10. PubMed ID: 17049838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antibodies as anticancer agents.
    Zafir-Lavie I; Michaeli Y; Reiter Y
    Oncogene; 2007 May; 26(25):3714-33. PubMed ID: 17530025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivalent antibodies: when design surpasses evolution.
    Cuesta AM; Sainz-Pastor N; Bonet J; Oliva B; Alvarez-Vallina L
    Trends Biotechnol; 2010 Jul; 28(7):355-62. PubMed ID: 20447706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational protein design: developing next-generation biological therapeutics and nanobiotechnological tools.
    Wilson CJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(3):330-41. PubMed ID: 25348497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
    Pardridge WM
    Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era.
    Juliano RL; Astriab-Fisher A; Falke D
    Mol Interv; 2001 Apr; 1(1):40-53. PubMed ID: 14993337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.